Sugammadex (Bridion®) – our first experience with the reversal of moderate rocuronium-induced neuromuscular block
Authors:
Adamus Milan 1; Hrabálek Lumír 2; Koutná Jiřina 1
Authors‘ workplace:
Klinika anesteziologie a resuscitace, Fakultní nemocnice a Lékařská fakulta Univerzity Palackého v Olomouci
1; Neurochirurgická klinika, Fakultní nemocnice a Lékařská fakulta Univerzity Palackého v Olomouci
2
Published in:
Anest. intenziv. Med., 21, 2010, č. 3, s. 128-133
Category:
Anaesthesiology - Original Paper
Overview
Objective:
To study the reversal of moderate rocuronium-induced neuromuscular block as part of balanced general anaesthesia with sugammadex 2 mg/kg.
Design:
Clinical, observational, retrospective, non-interventional study.
Setting:
Department of Anaesthesiology, University Hospital.
Materials and methods:
The reversal of moderate rocuronium-induced neuromuscular block with sugammadex (2 mg/kg) was retrospectively studied. We used TOF stimulation of the ulnar nerve at 15-s intervals and measured the accelerometric response of the adductor pollicis muscle (TOF-Watch® SX). Following spontaneous recovery to TOF-count = 2, sugammadex (2 mg/kg) was administered and the reversal of the block was recorded. We transferred the data (TOF-ratio, T1) via a link to the computer and presented the results using descriptive statistics and graphs.
Results:
We analysed the data from 18 males and 14 females. The mean age was 46 years, mean weight 74 kg, mean height 170 cm and mean BMI 25.84 kg/m2. The mean duration of anaesthesia was 64 minutes. During spontaneous recovery from the block, the reaction to the second impulse in TOF (TOF-count = 2) was detected as early as T1 = 19 %. Median (quartiles) of time to full recovery (TOF-ratio ≥ 0.9) was 97.5 (75; 130) s following sugammadex administration. Full recovery was observed in 13 % patients at 1 minute, in 72 % at 2 minutes and in all the patients at 3 minutes. No adverse effects following sugammadex administration were observed.
Conclusion:
Following sugammadex (2 mg/kg) administration, the reversal of moderate rocuronium-induced block was reliable and full recovery was reached within 3 minutes of sugammadex administration.
Keywords:
rocuronium – sugammadex – neuromuscular block – reversal
Sources
1. Lee, Ch., Katz, R. L. Have we learned how to relax our patients, by thinking outside the box? J. Crit. Care, 2009, 24, p. 1–4.
2. Fuchs-Buder, T., Claudius, C., Skovgaard, L. T., Eriksson, L. I., Mirakhur, R. K., Viby-Mogensen, J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol. Scan., 2007, 51, p. 789–808.
3. Murphy, G. S. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiologica, 2006, 72, p. 97–109.
4. Adamus, M., Koutná, J., Žáčková, D. Pooperační reziduální kurarizace na dospávacím pokoji – cisatrakurium vs. rokuronium: prospektivní studie. Anest. intenziv. Med., 2007, 18, p. 30–34.
5. Naguib, M., Kopman, A. F., Ensor, J. E. Neuromuscular monitoring and postoperative curarization: a meta-analysis. Br. J. Anaesth., 2007, 98, p. 302–316.
6. Murphy, G. S., Szokol, J. W., Marymount, J. H., Greenberg, S. B., Avram, M. J., Vender, J. S. Residual neuromuscular blockade and critical respiratory events on the Postanesthesia Care Unit. Anesth. Analg., 2008, 107, p. 130–137.
7. Debaene, B., Plaud, B., Dilly, M. P., Donati, F. Residual paralysis in the PACU after a single intubating dose of non-depolarizing muscle relaxant with an intermediate duration of action. Anesthesiology, 2003, 98, p. 1041–1048.
8. Kopman, A. F., Eikermann, M. Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia, 2009, 64 (Suppl. 1), p. 22–30.
9. Murphy, G. S., Szokol, J. W., Marymount, J. H. et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology, 2008, 103, p. 389–398.
10. Caldwell, J. E. Clinical limitations of acetylcholinesterase antagonists. J. Crit. Care, 2009, 24, p. 21–28.
11. Kovac, A. L. Sugammadex: the first selective binding reversal agent for neuromuscular block. J. Clin. Anesth., 2009, 21, p. 444–453.
12. Bom, A., Hope, F., Rutherford, S., Thomson, K. Preclinical pharmacology of sugammadex. J. Crit. Care, 2009, 24, p. 29–35.
13. Booij, L. H. D. J. Cyclodextrins and the emergence of sugammadex. Anaesthesia, 2009, 64 (Suppl. 1), p. 31–37.
14. Sorgenfrei, I. F., Norril, D. K., Larsen, B. V. The reversal of rocuronium induced neuromuscular block by the selective relaxant binding agent sugammadex. Anesthesiology, 2006, 104, p. 667–674.
15. Shields, M., Giovannelli, M., Mirakhur, R. K., Moppett, I., Adams, J., Hermens, Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br. J. Anaesth., 2006, 96, p. 36–43.
16. Suy, K., Morias, K., Cammu, G., Hans, P., van Duijnhoven, W. G. F. Effective reversal of moderate rocuronium or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology, 2007, 106, p. 283–288.
17. Pühringer, F., Blaszyk, M., Gammu, G., Sparr, H., Heeringa, M. Sugammadex achieves fast recovery from shallow neuromuscular blockade induced by rocuronium or vecuronium: dose-response studies. Eur. J. Anaesth., 2007, 24 (Suppl. 39), p. 111.
18. Plaud, B., Meretoja, O., Pohl, B., Mirakhur, R. K., Raft, J. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in paediatric and adult patients. Eur. J. Anaesth., 2007, 24, Suppl. 39, p. 124.
19. Blobner, M., Eriksson, L., Scholz, J., Hillebrand, A., Pompei, L. Sugammadex (2 mg/kg) significantly faster reverses shallow rocuronium-induced neuromuscular blockade compared with Neostigmine (50 μg/kg). Eur. J. Anaesth., 2007, 24, Suppl. 39, p. 125–126.
20. Blobner, M., Rietbergen, H., Hermens, Y., Mirakhur, R. Recovery from shallow rocuronium-induced neuromuscular blockade is consistently more rapid with sugammadex compared with neostigmine: results from a pooled analysis of phase 2 & 3 studies. Eur. J. Anaesth., 2008, 25, Suppl. 44, 9AP3-2.
21. Mirakhur, R. K. Sugammadex in clinical practice. Anaesthesia, 2009, 64, Suppl. 1, p. 45–54.
22. Vanacker, B. F., Vermeyen, K. M., Struys, M. M. et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth. Analg., 2007, 104, p. 563–568.
23. Alvarez-Gomez, J. A., Wattwill, M., Vanacker, B., Lora-Damayo, J. I., Khünl-Brady, K. S. Reversal of vecuronium induced shallow neuromuscular blockade is significantly faster with sugammadex compared with neostigmine. Eur. J. Anesth., 2007, 24, Suppl. 39, p. 124–125.
24. Lemmens, H. J. M., El-Orbany, M. I., Verry, J., Martin, G. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine. Anesthesiology, 2007, 107, A1578.
25. Lee, C., Jahr, J. S., Candiotti, K., Warriner, V., Zornow, M. H. Reversal of profound rocuronium NMB with sugammadex is faster than recovery from succinylcholine. Anesthesiology, 2007, 107, A988.
26. de Boer, H. D. Neuromuscular transmission: New concepts and agents. J. Crit. Care, 2009, 24, p. 36–42.
27. Caldwell, J. E., Miller, R. D. Clinical implications of sugammadex. Anaesthesia, 2009, 64, Suppl. 1, p. 66–72.
28. Adamus, M., Gabrhelík, T., Marek, O., Koutná, J., Trenkler, Š. Svalová relaxace na ARO České republiky 2006 – dotazníková studie. Anest. intenziv. Med., 2007, 18, p. 73–84.
Labels
Anaesthesiology, Resuscitation and Inten Intensive Care MedicineArticle was published in
Anaesthesiology and Intensive Care Medicine
2010 Issue 3
Most read in this issue
- Multiple organ dysfunction syndrome (MODS) – from molecules to the bedside
- Xenon inhalational anaesthesia in volunteers
- Sugammadex (Bridion®) – our first experience with the reversal of moderate rocuronium-induced neuromuscular block
- N-terminal pro-Brain natriuretic peptide (NT-proBNP) in acute brain disease: Elevated serum levels without sodium imbalance